Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study.

× No keyword cloud information.

3 in total

1. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors: F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal: JAMA Date: 2000-09-13 Impact factor: 56.272

2. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors: C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal: N Engl J Med Date: 2000-11-23 Impact factor: 91.245

3. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

Authors: Muhammad Mamdani; Paula A Rochon; David N Juurlink; Alex Kopp; Geoffrey M Anderson; Gary Naglie; Peter C Austin; Andreas Laupacis
Journal: BMJ Date: 2002-09-21

3 in total

25 in total

1. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database.

Authors: S Lugardon; M Lapeyre-Mestre; J L Montastruc
Journal: Eur J Clin Pharmacol Date: 2004-10-23 Impact factor: 2.953

2. Rebuttal: are drugs too expensive in Canada?

Authors: Joel Lexchin; Russell Williams; Jean Marion
Journal: Can Fam Physician Date: 2006-07 Impact factor: 3.275

Review 3. Economic evaluations in the canadian common drug review.

Authors: Andreas Laupacis
Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981

4. Development of NSAIDs prescription indicators based on health outcomes.

Authors: Rocío Fernández Urrusuno; Miguel Pedregal González; Ma Amparo Torrecilla Rojas
Journal: Eur J Clin Pharmacol Date: 2007-10-31 Impact factor: 2.953

5. Confounding control in healthcare database research: challenges and potential approaches.

Authors: M Alan Brookhart; Til Stürmer; Robert J Glynn; Jeremy Rassen; Sebastian Schneeweiss
Journal: Med Care Date: 2010-06 Impact factor: 2.983

Review 6. [New epidemiology of acute gastrointestinal hemorrhage].

Authors: H-R Koelz; M Arn
Journal: Chirurg Date: 2006-02 Impact factor: 0.955

7. Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern.

Authors: Louise Barnard; Dominic Lavoie; Nancy Lajeunesse
Journal: Drug Saf Date: 2006 Impact factor: 5.606

8. Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists: the tortoise and the hare revisited.

Authors: Brian D De Smet; A Mark Fendrick; James G Stevenson; Steven J Bernstein
Journal: J Gen Intern Med Date: 2006-07 Impact factor: 5.128

Review 9. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.

Authors: Jeffrey S Borer; Lee S Simon
Journal: Arthritis Res Ther Date: 2005-09-15 Impact factor: 5.156

10. A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example.

Authors: Tjeerd-Pieter van Staa; Hubert G Leufkens; Bill Zhang; Liam Smeeth
Journal: PLoS Med Date: 2009-12-08 Impact factor: 11.069